This acquisition is for four Illumina MiSeq i100 Plus genomic sequencing systems and the Illumina DRAGEN Bio-IT Platform to replace aging sequencers for the FDA’s Human Foods Program. The systems are needed to maintain continuity of sequencing methods, proprietary flow cells, reagents, software licenses, and manufacturer-supported components for mission-critical projects. The equipment will support high-throughput, cost-effective, and rapid sequencing for food safety surveillance, regulatory compliance, and novel genomic applications. No specific budget amount, performance location, or non-bid timelines are mentioned in the description. The opportunity is restricted to brand name or equal systems to ensure operational continuity.